- VeChain use-case soars as My Story is the second significant adoption.
- VET price rose 30%, showing signs of life for the first time after the market crash on May 19.
- A 26% upswing piercing the upper band of the supply barrier seems likely.
VeChain has been making headway when it comes to real-world applications of its blockchain. My Story is one such recent development that presents the use of blockchain to address specific problems. VET price seems to be rising after the recent debacle and hints at a continuation of the trend.
My Story, verifying marketing buzzwords via blockchain
My Story is a blockchain-based solution that helps an ecosystem of companies turn “marketing buzzwords into a true, verified story.” As the name indicates, the assurance solution allows companies to tell their stories and prove the authenticity of their products and services using distributed ledger technology, where data can be safely stored without worrying about manipulation.
The announcement reads:
The solution used for My Story™ is based on a public, decentralized and distributed ledger provided by Vechain, a leading blockchain provider and DNV partner. It is implementable for companies, as it is an ecosystem that includes user management and connectivity options for IoT devices, for example, and it is a scalable and affordable enterprise solution.
While the applications of this are plenty, My Story is working with two companies to tell the story of Italian wines from grape to bottle and guaranteeing the authenticity of fashionable clothes.
Recently, VeChain’s blockchain was also leveraged by ReSea Project to end the plastic ocean crisis. The data collected from this community-driven solution is stored on the blockchain.
Additionally, ReSea received certification from DNV, a VeChain partner, as proof of the initiative’s progress and traceability of the total collection process.
VeChain price continues to exude strength
VeChain price surged roughly 30% on May 24, signaling the increase in buyers. However, this rally slowed down as profit-booking intensified around the resistance level at $0.121, which coincides with the 100-day Simple Moving Average (SMA).
Now, VeChain price could either retrace 12% to the support barrier at $0.0984 and then advance higher or continue its climb from the current position ($0.110).
If the first scenario comes to pass, the buyers will have more time to accumulate, allowing the upswing to have more oomph. In this case, VET will first encounter the ceiling at $0.121, coinciding with the 100-day SMA. Breaching this confluence will signal the presence of massive buying pressure, which may help extend this ascent to the supply zone, ranging from $0.127 to $0.142.
All in all, this move would represent a 45% upswing.
However, if the retracement mentioned above fails to manifest, Vechain price might surge 26% to tag the resistance area’s upper boundary at $0.142.
VET/USDT 1-day chart
While the VeChain adoption seems to be going well, things might go awry if VET price slices below the $0.0825 support level. Such a move would invalidate the bullish thesis detailed above and trigger a 13% sell-off to the 200-day SMA at $0.0720.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.